



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/549,241	06/12/2006	Napoleone Ferrara	11669.0162USWO	5101
23552 7590 01/29/2008 MERCHANT & GOULD PC P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903				
EXAMINER				
GAMETT, DANIEL C				
ART UNIT		PAPER NUMBER		
1647				
MAIL DATE		DELIVERY MODE		
01/29/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/549,241

Applicant(s)

FERRARA ET AL.

Examiner

DANIEL C. GAMETT

Art Unit

1647

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 November 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 72-122 is/are pending in the application.
- 4a) Of the above claim(s) 102-121 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 72-101 and 122 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 12 September 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 09/12/2005, 11/30/2007
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

1. Applicant's election with traverse of claims 72-101 and 122 in the reply filed on 11/30/2007 is acknowledged. The traversal is on the ground(s) that the hematopoiesis stimulatory activity of Bv8, EG-VEGF, or a combination thereof, is a special technical feature of the claims that links Groups I and II so as to form a single inventive concept. This is not found persuasive because, while both Groups of invention generally address hematopoiesis, this biological phenomenon is not a technical feature of the claims. The claims define the invention. Claims 72-101 and 122 (Group I) are directed to methods comprising administration of Bv8, EG-VEGF, or a combination thereof, to achieve the effect of inducing proliferation of cells. Claims 102-121 (Group II) are drawn to methods comprising administering a Bv8 antagonist, EG-VEGF antagonist, or combination thereof, for the general purpose of treating an autoimmune disorder or a disorder associated with abnormal hematopoiesis; leukemias are recited as embodiments. Therefore, the two Groups are drawn to administration of completely different agents to achieve directly opposite results.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 102-121 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 11/30/2007.
3. Claims 72-101 and 122 are under consideration.

Information Disclosure Statement

4. The reference listed as Lin *et al.*, on the information disclosure statement filed 11/30/2007 has not been considered. It appears that no copy of this non-patent literature publication has been submitted in accordance with 37 CFR 1.98(a)(2).

Claim Objections

5. Claim 88 is objected to because of the following informalities: “lymphopenia” is not in any dictionary and appears to be a misspelling of “lymphopenia”. Appropriate correction is required.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claim 72-83, 85-99, 101 and 122 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The fact that a patent is directed to method entailing use of a compound, rather than to the compound *per se*, does not remove patentee's obligation to provide description of the compound sufficient to distinguish infringing methods from noninfringing methods (University of Rochester v. G.D. Searle & Co., 69 USPQ2d 1886 (CAFC 2004)). In this case, the claims are drawn to methods that comprise administration of genera of compounds recited as

Bv8, having at least 80% identity with an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, or EG-VEGF, having at least having at least 80% identity with amino acids 20-105 of SEQ ID NO:8; each induces proliferation of endothelial cells.

8. To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, compound to be administered is recited only by name in the independent claims; the factors present in the dependent claims are a partial structure in the form of a recitation of percent identity and the functional limitation of inducing proliferation of endothelial cells. The expression "80% identity with *an* amino acid sequence of SEQ ID NO:X" could be met by any peptide in which 4 amino acids are identical to any 5 consecutive amino acids in the reference sequence. Thus, structurally, the genus is immense. Even if the claims recited 80% identity with *the* amino acid sequence of SEQ ID NO:X, this would result in greater than 3×10^{32} possible sequences for the 86 amino acid (20-105 inclusive) EG-VEGF polypeptide of claim 82, for example. The number of polypeptides 80% identical over the full lengths of SEQ ID NO:2 or SEQ ID NO:4 would be much larger, as these sequences are 129 and 108 amino acids in length, respectively. Although structural conservation among the related polypeptides is documented, the specification does not identify any particular portion of the structure that must be conserved in order to preserve the recited function. The instant specification describes only polypeptides consisting of SEQ ID NOs: 2, 4, 6, or amino acids 20-105 of SEQ ID NO: 8, as examples meeting the structural and functional limitations of the

instant claims. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

9. *Vas-Cath Inc. v. Mahurkar*, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116).

10. With the exception of SEQ ID NOs: 2, 4, 6, and 8, the skilled artisan cannot envision the detailed chemical structure of the encompassed polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Possession may not be shown by merely describing how to obtain possession of members of the claimed genus or how to identify their common structural features. See *University of Rochester*, 358 F.3d at 927, 69 USPQ2d at 1895. One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

11. Therefore, only isolated polypeptides comprising the amino acid sequences set forth in SEQ ID NOs: 2, 4, 6, and 8, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear